G protein-coupled estrogen receptor correlates with Dkk2 expression and has prognostic impact in ovarian cancer patients

dc.contributor.authorFraungruber, Patricia
dc.contributor.authorKaltofen, Till
dc.contributor.authorHeublein, Sabine
dc.contributor.authorKuhn, Christina
dc.contributor.authorMayr, Doris
dc.contributor.authorBurges, Alexander
dc.contributor.authorMahner, Sven
dc.contributor.authorRathert, Philipp
dc.contributor.authorJeschke, Udo
dc.contributor.authorTrillsch, Fabian
dc.date.accessioned2023-09-13T12:11:51Z
dc.date.available2023-09-13T12:11:51Z
dc.date.issued2021
dc.date.updated2021-03-05T07:59:37Z
dc.description.abstractWnt pathway modulator Dickkopf 2 (Dkk2) and signaling of the G protein-coupled estrogen receptor (GPER) seem to have essential functions in numerous cancer types. For epithelial ovarian cancer (EOC), it has not been proven if either Dkk2 or the GPER on its own have an independent impact on overall survival (OS). So far, the correlation of both factors and their clinical significance has not systematically been investigated before. Expression levels of Dkk2 were immunohistochemically analyzed in 156 patient samples from different histologic subtypes of EOC applying the immune-reactivity score (IRS). Expression analyses were correlated with clinical and pathological parameters to assess for prognostic relevance. Data analysis was performed using Spearman’s correlations, Kruskal-Wallis-test and Kaplan-Meier estimates. Highest Dkk2 expression of all subtypes was observed in clear cell carcinoma. In addition, Dkk2 expression differed significantly (p<0.001) between low and high grade serous ovarian cancer. A significant correlation of Dkk2 with the cytoplasmic GPER expression was noted (p=0.001) but not for the nuclear estrogen receptor alpha (ERα) or beta (ERβ). Patients exhibiting both, high expression Dkk2 (IRS>4) and GPER (IRS>8), had a significantly better overall survival compared to patients with low expression (61 months vs. 33 months; p=0.024). Dkk2 and GPER expression correlates in EOC and combined expression of both is associated with improved OS. These findings underline the clinical significance of both pathways and indicate a possible prognostic impact as well as a potential for treatment strategies addressing interactions between estrogen and Wnt signaling in ovarian cancer.en
dc.identifier.issn1664-2392
dc.identifier.other1865924547
dc.identifier.urihttp://nbn-resolving.de/urn:nbn:de:bsz:93-opus-ds-135204de
dc.identifier.urihttp://elib.uni-stuttgart.de/handle/11682/13520
dc.identifier.urihttp://dx.doi.org/10.18419/opus-13501
dc.language.isoende
dc.relation.uridoi:10.3389/fendo.2021.564002de
dc.rightsinfo:eu-repo/semantics/openAccessde
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/de
dc.subject.ddc570de
dc.subject.ddc610de
dc.titleG protein-coupled estrogen receptor correlates with Dkk2 expression and has prognostic impact in ovarian cancer patientsen
dc.typearticlede
ubs.fakultaetChemiede
ubs.fakultaetFakultätsübergreifend / Sonstige Einrichtungde
ubs.institutInstitut für Biochemie und Technische Biochemiede
ubs.institutFakultätsübergreifend / Sonstige Einrichtungde
ubs.publikation.seiten8de
ubs.publikation.sourceFrontiers in endocrinology 12 (2021), No. 564002de
ubs.publikation.typZeitschriftenartikelde

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
fendo-12-564002.pdf
Size:
1.43 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.39 KB
Format:
Plain Text
Description: